Cargando…

Assessing the Clinical Benefit of Systemic Adjuvant Therapies for Early Breast Cancer

Oncologic therapy is currently undergoing significant changes. A number of innovative targeted medications currently in clinical development have raised high expectations. With that in mind, discussions about terms such as “clinical benefit” and “clinical relevance” are highly topical. This also app...

Descripción completa

Detalles Bibliográficos
Autores principales:	Möbus, Volker, Hell, Susanne, Schmidt, Marcus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Georg Thieme Verlag KG 2017
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5658231/ https://www.ncbi.nlm.nih.gov/pubmed/29093601 http://dx.doi.org/10.1055/s-0043-119542

Ejemplares similares

Research Status of Systemic Adjuvant Therapy for Early Breast Cancer
por: Hu, Wenyu, et al.
Publicado: (2023)

Final results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancer
por: Müller, Volkmar, et al.
Publicado: (2010)

Long-term (up to 16 months) health-related quality of life after adjuvant tailored dose-dense chemotherapy vs. standard three-weekly chemotherapy in women with high-risk early breast cancer
por: Brandberg, Yvonne, et al.
Publicado: (2020)

Comparative clinical benefits of systemic adjuvant therapy for paradigm solid tumors
por: Kirkwood, John M., et al.
Publicado: (2012)

Recent advances in systemic therapy. Advances in adjuvant systemic chemotherapy of early breast cancer
por: López-Tarruella, Sara, et al.
Publicado: (2009)

Editorial: Risks and Benefits of Adjuvants to Cancer Therapies
por: Dong, Peixin, et al.
Publicado: (2022)

Adjuvant Systemic Anti-cancer Therapy in Early Breast Cancer During the COVID-19 Pandemic: Differences between Clinicians and Patients in Perception of Treatment Risks and Benefits
por: Gatfield, E.R., et al.
Publicado: (2020)

Matters of the heart: cardiac toxicity of adjuvant systemic therapy for early-stage breast cancer
por: Towns, K., et al.
Publicado: (2008)

A Risk-benefit Assessment Approach to Selection of Adjuvant Chemotherapy in Elderly Patients with Early Breast Cancer: A Mini Review
por: Agarwala, Vivek, et al.
Publicado: (2017)

Adjuvant endocrine therapy for premenopausal women with early breast cancer
por: Bao, Ting, et al.
Publicado: (2007)

Current treatment of early breast cancer: adjuvant and neoadjuvant therapy
por: Miller, Elizabeth, et al.
Publicado: (2014)

Chromosome instability and benefit from adjuvant anthracyclines in breast cancer
por: Munro, A F, et al.
Publicado: (2012)

Adjuvant systemic therapy in older women with breast cancer
por: Leone, Julieta, et al.
Publicado: (2016)

Assessing Adherence to Adjuvant Hormone Therapy in Breast Cancer Patients in Routine Clinical Practice
por: Camejo, Natalia, et al.
Publicado: (2023)

Adjuvant tamoxifen for early breast cancer.
por: Smith, I.
Publicado: (1988)

Adjuvant chemotherapy for early breast cancer.
por: Henderson, I. C.
Publicado: (1990)

Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays
por: Hyams, David M., et al.
Publicado: (2017)

Safety of adjuvant endocrine therapies in hormone receptor–positive early breast cancer
por: Sehdev, S., et al.
Publicado: (2009)

Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy
por: Arpino, Grazia, et al.
Publicado: (2015)

Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer
por: van Hellemond, Irene E. G., et al.
Publicado: (2018)

The PROMISe to increase precision in adjuvant therapy for early breast cancer: To “Type” or to “Print”?
por: Cardoso, Fatima, et al.
Publicado: (2018)

Extended Adjuvant Endocrine Therapy in Early Breast Cancer Patients—Review and Perspectives
por: Bekes, Inga, et al.
Publicado: (2023)

Early detection of breast cancer: benefits and risks of supplemental breast ultrasound in asymptomatic women with mammographically dense breast tissue. A systematic review
por: Nothacker, Monika, et al.
Publicado: (2009)

Update on Adjuvant Chemotherapy for Early Breast Cancer
por: Rampurwala, Murtuza M, et al.
Publicado: (2014)

Bisphosphonates in the adjuvant treatment of early breast cancer
por: Gnant, M
Publicado: (2009)

The Clinical Benefit of Adjuvant Therapy in Long-Term Survival of Early-Stage Ampullary Carcinoma: A Single Institutional Experience
por: Manne, Ashish, et al.
Publicado: (2020)

S-phase fraction and survival benefit from adjuvant chemotherapy or radiotherapy of breast cancer.
por: Stål, O., et al.
Publicado: (1994)

Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients
por: de Boo, Leonora W., et al.
Publicado: (2022)

Developing Questions to Assess and Measure Patients’ Perceived Survival Benefit from Adjuvant Endocrine Therapy in Breast Cancer: A Mixed Methods Pilot Study
por: Tawfik, Bernard, et al.
Publicado: (2023)

Clinical Utility of Aromatase Inhibitors as Adjuvant Treatment in Postmenopausal Early Breast Cancer
por: Loaiza-Bonilla, Arturo, et al.
Publicado: (2013)

Characteristics and Clinical Outcome of Breast Cancer Patients with Asymptomatic Brain Metastases
por: Laakmann, Elena, et al.
Publicado: (2020)

Adjuvant chemotherapy and HER-2-directed therapy for early-stage breast cancer in the elderly
por: Sun, J, et al.
Publicado: (2017)

Patients' preferences for adjuvant endocrine therapy in early breast cancer: what makes it worthwhile?
por: Duric, V M, et al.
Publicado: (2005)

Electronic brachytherapy as adjuvant therapy for early stage breast cancer: a retrospective analysis
por: Dooley, William C, et al.
Publicado: (2011)

Status of adjuvant endocrine therapy for breast cancer
por: Schiavon, Gaia, et al.
Publicado: (2014)

Adjuvant therapy of HER2(+ )breast cancer
por: Winer, EP
Publicado: (2009)

Adjuvant chemotherapy could benefit early-stage ER/PR positive mucinous breast cancer: A SEER-based analysis
por: Gao, Hong-Fei, et al.
Publicado: (2020)

Population-based estimates of overtreatment with adjuvant systemic therapy in early breast cancer patients with data from the Netherlands and the USA
por: Ragusi, M. A. A., et al.
Publicado: (2022)

Optimal indications of endocrine therapy alone as adjuvant systemic treatment of breast cancer
por: Horii, R, et al.
Publicado: (2007)

Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer
por: Li, Li, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ouk76dlonusc8i6gml04eainam